Why Is Iovance (IOVA) Stock Price Up 12.52% Today, August 20? Strong Cancer Therapy Sales and Analyst Upgrades Extend the Rally

Iovance Biotherapeutics shares extended a post-earnings re-rating after strong Q2 revenue ($99.3m, +66% y/y) and improved gross margin (56%), reinforcing confidence in commercial traction for Amtagvi. Multiple analyst target upgrades added support, despite management maintaining its 2026 revenue range ($350m–$370m). With no new same-day catalyst, the move reflects momentum tied to execution and guidance credibility, alongside near-term overbought conditions.